Prof Neeraj Agarwal speaks to ecancer about the final overall survival with talazoparib and enzalutamide as first-line treatment in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) in phase 3 TALAPRO-2 trial.

This trial explores the combination of talazoparib and enzalutamide for treating metastatic castration-resistant prostate cancer.

The study reveals a 33% reduction in progression risk and a 20% decrease in death risk, leading to improved median overall survival over eight months.

Benefits are noted across various demographics, especially in patients with HRR gene alterations.

Adverse events are manageable, emphasising the need for NGS testing to identify mutations and optimise treatment.